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Ocular involvement can be quite symptomatic in patients with chronic graft-versus-host disease (GVHD). The
prevalence of and risk factors for ocular GVHD and its impact on quality of life (QOL) in patients with chronic
GVHD were studied in a prospective, multicenter, longitudinal, observational study. This study enrolled 342
patients with 1483 follow-up visits after allogeneic hematopoietic cell transplantation. All patients in this
analysis were diagnosed with chronic GVHD requiring systemic treatment and enrolled within 3 months of
chronic GVHD diagnosis. The symptom burden of ocular GVHD was based on the degree of dry eye symptoms,
frequency of artiﬁcial tear usage, and impact on activities of daily living. Patients’ QOL was measured by self-
administered questionnaires. Variables associated with ocular GVHD at enrollment and subsequent new-
onset ocular GVHD and the associations with QOL were studied. Of the 284 chronic GVHD patients, 116
(41%) had ocular GVHD within 3 months of chronic GVHD diagnosis (“early ocular GVHD”). Late ocular GVHD
(new onset > 3 months after chronic GVHD diagnosis) occurred in 64 patients. Overall cumulative incidence
at 2 years was 57%. Female gender (P ¼ .005), higher acute GVHD grade (P ¼ .04), and higher prednisone dose
at study entry (P ¼ .04) were associated with early ocular GVHD. For patients who did not have ocular GVHD
within 3 months of chronic GVHD diagnosis, presence of prior grades I to IV acute GVHD (HR 1.78, P ¼ .04)
was associated with shorter time to late ocular GVHD, whereas female donoremale recipient (HR .53, P ¼ .05)
was associated with longer time to late ocular GVHD onset. Using all visit data, patients with ocular GVHD had
worse QOL, as measured by Functional Assessment of Cancer Therapy Bone Marrow Transplantation (P ¼
.002), and greater chronic GVHD symptom burden, as measured by the Lee symptom overall score excluding
the eye component (P < .001), compared with patients without ocular GVHD. In conclusion, this large,
multicenter, prospective study shows that ocular GVHD affects 57% of patients within 2 years of chronic GVHD
diagnosis. Women, patients on higher doses of prednisone at study entry, and those with a history of acute
GVHD were at higher risk for ocular GVHD. Strong evidence suggests that ocular GVHD is associated with
worse overall health-related QOL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION curative intent [1,2]. Graft-versus-host disease (GVHD)
Since the ﬁrst successful bone marrow transplantation in
1968, allogeneic hematopoietic cell transplantation (HCT) is
used with increasing frequency for treatment of hemato-
logical disorders (both malignant and nonmalignant) withdgments on page 1690.
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ty for Blood and Marrow Transplantation.caused by alloreactive donor T cells remains an important
cause of nonrelapse mortality and morbidity after allogeneic
HCT [3]. Chronic GVHD typically starts more than 3 months
after transplant and may persist for many years. Chronic
GVHD most often involves the mouth and skin but can also
affect multiple sites, such as eyes, gastrointestinal tract, liver,
lungs, and genital tract [4,5].
Ocular GVHD reportedly occurs in more than 50% of
allogeneic HCT recipients with chronic GVHD [5]. The most
frequent ocular symptoms are a sensation of dryness,
Table 1
Patient Characteristics at Study Enrollment (N ¼ 342)
Variable No. of Cases (%)
Age, yr, median (range) 51 (19-79)
Recipient gender
Male 190 (56%)
Female 152 (44)
Male recipientefemale donor 92 (27)
Transplant type
Myeloablative 196 (58)
Nonmyeloablative 143 (42)
Donor status
Matched related 145 (43)
Matched unrelated 142 (42)
Mismatched 53 (15)
Prior acute GVHD
Yes 224 (66)
No 118 (34)
Ocular GVHD
Yes 116 (34)
No 168 (49)
Unclassiﬁable at enrollment (missing either
clinician or patient information)
58 (17)
Table 2
Ocular Characteristics of Early Ocular GVHD* Patients (n ¼ 116)
Variable No. of Cases (%)
NIH eye score
0 0 (0)
1 82 (71)
2 32 (27)
3 2 (2)
Schirmer’s test (worst eye)
>10 mm 30 (26)
5-10 mm 29 (25)
<5 mm 30 (26)
Missing 27 (23)
* Early ocular GVHD: ocular GVHD onset within 3 months after diagnosis
of chronic GVHD.
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all parts of the eye, but the ocular surface is the most com-
mon level of involvement [6-8]. Conjunctival involvement
has been associated with higher mortality [9] and worse
quality of life (QOL) [10] in prior single-centered and small-
grouped reports.
QOL is deﬁned as the general well-being of individuals
and societies [11]. It is a multidimensional concept, and
health is one of the important dimensions of overall QOL. The
QOL in patients with ocular disorders can be affected by
ocular symptoms, such as blurred vision, severe photo-
phobia, or discomfort that makes it uncomfortable to keep
eyes open [12-14]. Affected patients might not be able to
drive, read, watch television, or perform other common ac-
tivities in their routine daily life. In this studywe describe the
epidemiology of ocular GVHD symptoms in patients with
chronic GVHD, perform a risk factor analysis, and describe
the impact of ocular involvement on QOL.
METHODS
Data were derived from the Chronic GVHD Consortium, a multicenter
observational cohort study of chronic GVHD-affected HCT recipients. The
rationale and design of this cohort study have been previously described
[15] . Patients with chronic GVHD requiring systemic treatment were
enrolled if the time from onset of GVHD was 2 years or less. Cases were
deﬁned as incident if onset of chronic GVHD was within 3 months of study
enrollment and prevalent if onset of chronic GVHD was >3 months of study
enrollment. For this analysis only incident cases were included. The study
protocol was approved by the institutional review board of each partici-
pating center, and all participants or their guardians gave written informed
consent.
Patients had detailed assessments by the transplant clinician or trained
provider at prespeciﬁed time points as required by the protocol using a
variety of assessment tools [15]. Scoring of chronic GVHD was done using
the National Institutes of Health (NIH) consensus criteria [16]. Ocular
involvement was scored on a scale from 0 to 3 and depended on the degree
of dry eye symptoms, frequency of eye drops or intervention for dry eye, and
impact on activities of daily living [17]. At these visits, patients completed
detailed QOL questionnaires, including the Functional Assessment of Cancer
Therapy Bone Marrow Transplantation (FACT-BMT) [18,19]; the Short Form
36 (SF-36) Health Survey, which provides a Physical Component Score and
Mental Component Score [20,21]; the Human Activity Proﬁle (HAP),
providing a Maximum Activity Score [22], Adjusted Activity Score, and
modiﬁed HAPAdjusted Activity Score [23]; and the Lee symptom score [24].
The QOL metrics were not designed speciﬁcally for ocular disorders but
measure a person’s multidimensional QOL.
Deﬁnitions
For this study, the ocular GVHD group was deﬁned as eye involvement
reported by both the clinician (NIH 0-3 eye score > 0) and patient (eye
worst 0-10 score > 1 or Lee symptom eye score > 20) [25]. It is likely that
risk factors associated with ocular GVHD may vary depending on time of
onset of ocular GVHD in relation to development of systemic chronic
GVHD. Thus, early ocular GVHD was deﬁned as the onset of ocular
involvement at study enrollment, and late ocular GVHD was deﬁned as
onset 3 or more months after the diagnosis of chronic GVHD. Ocular as-
sessments before HCT or before study enrollment were not routinely
performed.
Statistical Analysis
Descriptive statistics, including continuous variables and categorical
variables, were calculated and are reported in Tables 1 and 2. Variables
analyzed were age at HCT, patient gender, donor and patient gender
combination, preparative regimen intensity, donor match status, source
of stem cells, prior acute GVHD, maximum acute GVHD grade (overall,
liver, gastrointestinal, and skin), underlying diseases, disease status,
platelet count at onset and enrollment, bilirubin level at onset and
enrollment, prednisolone dose at onset and enrollment, worst Schirm-
er’s test at enrollment, study site (Fred Hutchinson Cancer Research
Center [FHCRC] versus others), and duration from treatment to
enrollment.
Univariable and multivariable logistic regression models were ﬁt to
identify risk factors that were associated with ocular GVHD at enrollment.
To identify risk factors associated with the development of ocular GVHD atsubsequent follow up, Cox regressions were ﬁt for patients who did not
have ocular GVHD at enrollment (N ¼ 168). Relapse and death before the
onset of ocular GVHD were treated as competing events. Cox regressions
were also ﬁt for overall survival and nonrelapse mortality of the 2 cohorts
(chronic GVHD with and without ocular GVHD at study enrollment).
Covariates signiﬁcantly associated with outcomes were included for
adjustment, including platelet count (<100,000/mL or 100,000/mL), donor
gender combination (femaleemale or others), bilirubin (2 mg/dL or
higher), and NIH global severity (mild or less, moderate, or severe). Linear
mixed models with random patient effect were ﬁt for evaluating the ocular
involvement associated with QOL, including functional and symptom
measures, adjusted for signiﬁcant clinical covariates. The covariates
included study site (FHCRC or others), months since enrollment, platelet
count (<100,000/mL or 100,000/mL), NIH global severity (mild or less,
moderate, or severe), bilirubin (2 mg/dL or higher), overlap or classic, and
prior acute GVHD. P < .05 was considered statistically signiﬁcant. Statistical
analyses were performed using SAS/STAT software, version 9.4 (SAS Insti-
tute, Inc., Cary, NC) and R version 3.0.3 (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
General characteristics of the patients included in this
study are presented in Table 1. This study included 342 adult
patients who had 1483 visits. The median follow-up time
was 28 months from enrollment in the study (range, 4 to 66).
The cumulative incidence of all ocular GVHD at 2 years after
enrollment was 57% (95% conﬁdence interval [CI], 52% to
63%). The incidence of ocular GVHD between FHCRC and
other centers was also analyzed, and no signiﬁcance was
noted (P ¼ .49).
Figure 1. Cumulative incidence of subsequent late ocular GVHD (deﬁned as
ocular GVHD onset > 3 months after diagnosis of chronic GVHD) among pa-
tients without ocular GVHD at study enrollment (n ¼ 64).
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Of the 342 patients, 284 patients (83%) had complete
clinician- and patient-reported ocular data at study enroll-
ment. Of the 284 patients, 116 (41%) had ocular GVHD
conﬁrmed by both clinician and patient report within 3
months of chronic GVHD diagnosis (“early ocular GVHD”)
(Table 2). Most early ocular GVHD patients (71%) had mild
ocular symptoms (NIH eye score of 1). Among the 116 early
ocular GVHD patients, Schirmer’s test was measured in 89
patients (77%), of which 59 patients (66%) had a mean value
of 10mm or less. In amultivariable analysis, female sex (odds
ratio [OR], 2.14; 95% CI, 1.26 to 3.63; P ¼ .005), overall
maximum acute grade (OR, 1.32; 95% CI, 1.01 to 1.73; P¼ .04),
and higher prednisone dose at study entry (OR, 2.04; 95% CI,
1.04 to 4.00; P¼ .04) were associated with early ocular GVHD
(Table 3).
Development and Risk Factor Analysis of Late Ocular
GVHD
Late ocular GVHD (new onset after study enrollment)
occurred in 64 patients who were conﬁrmed not to have
ocular GVHD at enrollment. The cumulative incidence of late
ocular GVHD at 2-year postenrollment was 37% (95% CI, 30%
to 46%) (Figure 1). In multivariable modeling, presence of
prior grades I to IV acute GVHD (hazard ratio [HR] 1.78, P ¼
.04) was associated with shorter time to late ocular GVHD,
whereas female donoremale recipient (HR .53, P ¼ .05) was
associated with longer time to late onset ocular GVHD
(Table 4).
Eighteen of 58 patients (31%) whose ocular GVHD could
not be classiﬁed at enrollment because of missing clinician or
patient information subsequently had conﬁrmed ocular
GVHD later in their course. These patients were excluded
from the analysis of late ocular GVHD predictors because we
were uncertain if they had early- or late-onset ocular GVHD.
Survival and Nonrelapse Mortality
In multivariate Cox models with ocular GVHD as a time-
varying covariate, ocular GVHD was not associated with
survival (HR 1.08, P ¼ .76) or subsequent nonrelapse mor-
tality (HR 1.27, P ¼ .48).
Analysis between QOL and Ocular GVHD
Table 5 shows the association of ocular GVHD with
patient-reported QOL, using all available visit data adjusted
for center effect, months since enrollment, platelet count,
NIH severity, bilirubin, prior acute GVHD, and overlap versus
classic chronic GVHD. The association between QOL and
ocular involvement was signiﬁcant, especially in the FACT-
BMT score (P < .01) despite adjusting for clinical factors.
The Lee symptom score overall (excluding the eye compo-
nent to avoid bias from eye symptoms) was also highlyTable 3
Multivariable Analysis of Risk Factors Associated with Early Ocular GVHD*
Involvement in Chronic GVHD Patients at Enrollment (n ¼ 116)
Covariate Effect OR 95% CI P
Patient gender Female vs. Male 2.14 1.26-3.63 .005
Maximum acute
GVHD grade: overall
Continuous 0-4 1.32 1.01-1.73 .04
Prednisone dose at
enrollment
Continuous 2.04 1.04-4.00 .04
* Early ocular GVHD: ocular GVHD onset within 3 months after diagnosis
of chronic GVHD.associated with ocular involvement (P< .001). The other QOL
questionnaires, including the SF-36 and HAP, did not show
signiﬁcant associations with ocular involvement (P > .05).
DISCUSSION
This study describes the high incidence of symptomatic
ocular GVHD in patients with established chronic GVHD in a
longitudinal prospective cohort. In our cohort, 41% of pa-
tients had ocular GVHD symptoms within 3 months after
diagnosis of chronic GVHD and another 23% developed
ocular GVHD by 2 years after chronic GVHD onset for a 2-year
cumulative incidence of 57%. Thus, patients with chronic
GVHD who do not have ocular GVHD at onset of chronic
GVHD remain at signiﬁcant risk of subsequently developing
eye symptoms later and should be carefully monitored.
Some study limitations should be noted. We categorized
ocular GVHD according to the tools recommended by the
2005 NIH consensus conference on criteria for clinical trials
in chronic GVHD [16]. These assessments were designed to
be collected from transplant providers and patients and not
require subspecialists [16,26]. Indeed, many patients in our
study were managed by their transplant physicians and not
by ophthalmologists. Although Schirmer’s test was per-
formed in most patients, results are not used in severity
scoring because they are known to be unreliable [25,27,28].
The change in light, humidity, and temperature and patient
anxiety may interfere with the tear reﬂex [27]. The paper’sTable 4
Multivariable Analysis of Risk Factors Associated with Late Ocular GVHD*
Involvement (n ¼ 168, event n ¼ 64)
Covariate Effect HR 95% CI P
Prior grades I-IV
acute GVHD
Yes vs. no 1.78 1.04-3.20 .04
Donorepatient gender
combination
Female into
male vs. others
.53 .27-.96 .05
* Late ocular GVHD: ocular GVHD onset > 3 months after diagnosis of
chronic GVHD.
Table 5
Association between QOL and Ocular GVHD in Chronic GVHD Patients
QOL Metric Ocular GVHD Estimate P
FACT-BMT No 0* .002
Yes 3.0
Lee Scorey No 0* <.001
Yes 2.9
* Estimate 0, reference category.
y Lee symptom score, eye component excluded.
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on the lid margin are also the factors that can explain the
large discrepancies in the reported repeatability of the
Schirmer’s test [28].
We acknowledge that other etiologies besides ocular
GVHD could contribute to dry eye symptoms in our popu-
lation and could confound the analyses. A comprehensive
assessment by ophthalmologists would provide more
detailed, and likely more accurate, information about ocular
involvement, but referral is not uniformly practiced. In
addition, multiple consensus criteria for severity scoring
have been proposed by the ophthalmology community, but
none has been validated, suggesting that although the eval-
uation may be more complete, the ability to use that infor-
mation to quantify the severity of involvement is not robust
yet [17]. A recent analysis compared the Japanese dry eye
score and the Dry Eye Workshop Score with to the NIH eye
score [26] and found excellent correlation among the 3
scoring systems, lending support to the accuracy of trans-
plant physicians’ in assessing severity. However, a prospec-
tive study using ophthalmology examinations as the gold
standard is still necessary and important for further evalua-
tion of ocular GVHD.
Risk factors for ocular GVHD have been reported in
retrospective studies. In addition to global GVHD, prior acute
skin GVHD and male recipients of female donors were re-
ported as 2 independent risk factors for ocular GVHD [29]. A
higher incidence of ocular GVHD after peripheral blood stem
cell transplantation than after bone marrow transplantation
or cord blood transplantationwas reported by Uchino et al. in
2012 [30]. In our prospective study, independent risk factors
for early ocular GVHD included female sex, more severe
acute GVHD, and higher prednisone dose at enrollment. Fe-
male predilection for early ocular GVHD in this study (me-
dian age 51 years) is compatible with the predisposing
factors for dry eye syndrome, such as middle age and female
gender [31]. The biological reasons for these associations
remain unknown but may involve common pathways.
Interestingly, it seems that acute GVHD could predict
development of early ocular GVHD as well as late ocular
GVHD. In multivariable modeling, presence of prior grades I
to IV acute GVHD was associated with shorter time to late
ocular GVHD, whereas female donoremale recipient was
associated with longer time to late ocular GVHD onset. These
results should help deﬁne risk stratiﬁcation of patients in
future clinical trials addressing prevention of ocular GVHD.
QOL measures capture the impact of medical conditions
on physical, social, emotional, cognitive, work or role related,
and spiritual aspects of life. GVHD has consistently been
shown to have amajor impact on patients’QOL. Lee et al. [32]
showed that both grades II to IV acute and chronic GVHD
were associated with worse QOL after HCT. Pallua et al. [33]
also found that patients suffering from chronic GVHD
showed worse role functioning and global QOL and had ahigher likelihood of taking chronic medications. Pidala et al.
[34] reported that chronic GVHD severity deﬁned by NIH
criteria was independently associated with QOL. Riemens
et al. [10] used 2 questionnaires, the Visual Function
Questionnaire-25 and the Ocular Surface Disease Index, to
assess vision-related QOL in 2014. Their results showed that
patients who developed ocular GVHD (N¼ 14) have impaired
visual QOL.
In this study, we focused on the relationship between
ocular GVHD and health-related QOL instead of vision-
related QOL to study the impact of dry eye symptoms on
general QOL. Several different questionnaires, including
FACT-BMT, SF-36, HAP, and Lee symptom score, were used to
assess the QOL of ocular GVHD patients. FACT-BMT is an
outcome measure for health-related QOL, SF-36 is a measure
more about general health, and HAP measures functional
performance and activity limitation in adults. We found that
FACT-BMTand Lee symptom score (without the eye subscale)
showed signiﬁcant differences between patients with and
without ocular GVHD symptoms, adjusting for other clinical
factors. The association of ocular GVHD and FACT-BMT and
no association with SF-36 and HAP may be due to the char-
acteristics of ocular GVHD, which is an ocular surface disor-
der causing eye discomfort but not necessarily affecting
vision to impact activity and functional performance. To our
knowledge, this is the ﬁrst prospective study investigating
the association of ocular GVHD and health-related QOL.
There was no correlation with SF-36 and HAP.
In conclusion, we found that patients with more severe
acute GVHD developed ocular GVHD coincident with their
diagnosis of chronic GVHD and remained at higher risk for
subsequent late-onset ocular GVHD. Approximately a third of
patients with chronic GVHD had ocular GVHD at diagnosis,
whereas almost a fourth developed ocular GVHD at later
time points. A signiﬁcant relationship between ocular GVHD
and nonevision-related QOL and nonocular GVHD symp-
toms was also revealed in this study. Ocular GVHDmay cause
permanent destruction of lacrimal glands, resulting from an
increase in the number of stromal ﬁbroblasts and excessive
ﬁbrosis in the extracellular matrix of the lacrimal glands [35].
Early initiation of topical cyclosporine A .05% in ocular GVHD
patients could relieve patients’ dry eye symptoms and may
reduce the inﬂammatory response in the lacrimal glands
[36]. Ideally, prophylactic or pre-emptive clinical trial
(NCT00755040, pending analyses) strategies before the
onset of irreversible dry eye syndrome are needed.
Comprehensive ophthalmologic assessment should be un-
dertaken in patients at high risk for ocular GVHD and in
patients with ocular symptoms. Preventive evaluation at set
time points after transplant to screen for asymptomatic
ocular GVHD is encouraged.ACKNOWLEDGMENTS
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